Steve Ryder
Impact in
- Pharmacology top 0.5%
- Cannabis and Cannabinoid Research
-
- Trauma, Hemostasis, Coagulopathy, Resuscitation
Papers in
- Oncology 5
- PARP inhibition in cancer therapy 2
-
- Epilepsy research and treatment 2
- Co-authors
- Jos Kleijnen (20 shared papers)Penny F. Whiting (4 shared papers)Kate Misso (3 shared papers)Nigel Armstrong (23 shared papers)Steven Duffy (10 shared papers)Robert F. Wolff (6 shared papers)Sohan Deshpande (4 shared papers)Shona Lang (2 shared papers)
- Journals
- PharmacoEconomics (9 papers)Health Technology Assessment (7 papers)Current Medical Research and Opinion (1 paper)Annals of Oncology (1 paper)Clinical Epidemiology (1 paper)
- Partner nations
- United KingdomNetherlandsUnited States
In The Last Decade
Steve Ryder
27 papers receiving 3.0k citations
Steve Ryder's Hit Papers
Peers
Comparison fields: 5 of 137
- Pharmacology 1.4k
- Critical Care and Intensive Care Medicine 196
- Toxicology 133
- Hepatology 124
- Cellular and Molecular Neuroscience 275
Countries citing papers authored by Steve Ryder
This map shows the geographic impact of Steve Ryder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Ryder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Ryder more than expected).
Fields of papers citing papers by Steve Ryder
This network shows the impact of papers produced by Steve Ryder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Ryder. The network helps show where Steve Ryder may publish in the future.
Co-authors
The 25 scholars most cited alongside Steve Ryder, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cannabinoids for Medical Use Hit paper breakdown → | 2015 | 1656 |
| 2 | 2017 | 384 | |
| 3 | 2015 | 241 | |
| 4 | 2019 | 180 | |
| 5 | 2007 | 148 | |
| 6 | 2015 | 96 | |
| 7 | 2014 | 86 | |
| 8 | 2015 | 68 | |
| 9 | 2016 | 55 | |
| 10 | 2021 | 54 | |
| 11 | 2013 | 43 | |
| 12 | 2019 | 18 | |
| 13 | 2019 | 16 | |
| 14 | 2016 | 14 | |
| 15 | 2020 | 13 | |
| 16 | 2005 | 11 | |
| 17 | 2020 | 10 | |
| 18 | 2022 | 6 | |
| 19 | 2018 | 5 | |
| 20 | 2020 | 5 |
About Steve Ryder
Steve Ryder is a scholar working on Oncology, Psychiatry and Mental health, Pathology and Forensic Medicine, Hepatology and Pulmonary and Respiratory Medicine, having authored 29 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cannabis and Cannabinoid Research (2 papers), Botulinum Toxin and Related Neurological Disorders (2 papers), Acute Lymphoblastic Leukemia research (2 papers), PARP inhibition in cancer therapy (2 papers), Epilepsy research and treatment (2 papers), Lymphoma Diagnosis and Treatment (2 papers), Pain Mechanisms and Treatments (2 papers) and Diabetes Management and Research (2 papers). The work is most often cited by research in Pharmacology (1.4k citations), Critical Care and Intensive Care Medicine (196 citations), Toxicology (133 citations), Hepatology (124 citations) and Cellular and Molecular Neuroscience (275 citations). Steve Ryder has collaborated with scholars based in United Kingdom, Netherlands and United States. Frequent co-authors include Jos Kleijnen, Penny F. Whiting, Kate Misso, Nigel Armstrong, Steven Duffy, Robert F. Wolff, Sohan Deshpande, Shona Lang, Marcello Di Nisio and Adrián Vladimir Hernández. Their work appears in journals such as PharmacoEconomics, Health Technology Assessment, Current Medical Research and Opinion, Annals of Oncology and Clinical Epidemiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.